ImetelChat

Geron has been a reliable stock to short. It is a small biotech company that has one product, typically the profile of a company that will ultimately fail. That image was damaged by the FDA approval (clean, with no black box labels). New reenforced approvals from Europe are needed now (EMA, MHRA/UK)...

Dr. Aleksandra Rizo --- What is she doing now? Does "compound #2" involve any of the novel Vividion (Bayer) molecules that attracted her to her new job (President of Vividion)? Presumably, she still has a keen interest in Rytelo and its future. ===== Previous (Aug 7) Dr. Rizo will be part of Rytelo...

We still do not know what compound #2 is composed of, but likely it has exceeded the results in the reference material, perhaps with an oral path. I don't believe Geron would be so aggressive unless they were totally confident in Rytelo and its future. The European approvals seem ensured, but one n...

Rytelo is focusing on 3 blood cancers (MDS, MF, AML) with many successes. Certainly, Geron's PPS is being held under $5 by the market (hedge funds), independently of the continuing good medical and scientific news about Rytelo. Perhaps, that is finally changing. The FDA approval process for one feat...

As we sit on our hands waiting for European approvals, I am reflecting on some of the comments from past days. Are they valid or are they exaggerations? EMA and MHRA/UK approvals appear to be very likely, but one never knows until it happens. These approvals are a necessity for the investment commu...

rccola -We will have to wait and see. JS (IMHO) would tend to be very conservative (considering previous lawsuits) about anything that he would say to the public about any future European approvals. I am hoping that at least one of the approvals (EMA, MHRA/UK) would occur in 2024 (perhaps before ASH...

New approvals needed --- Rytelo has been approved by the FDA. However, before the PPS can get to over $5 (and stay there), the confirmation approvals from the Europeans (EMA, MHRA/UK) must be a matter of record. The speculation has been all over the place from next week, in October, before ASH2024 ...

We seem to be in a prolonged waiting period for European approvals. As far as I can tell, all of the information coming forward about Rytelo and its follow-ons continues to be upbeat and positive. The last quarter of 2024 will be full of surprises. November 5 will be a very important date (ASH2024 a...

ASH2024 ---Abstracts available online November 5, 2024, 9:00 a.m. Eastern time The 66th ASH Annual Meeting and Exposition will be held in San Diego, California from December 7-10, 2024. The event will take place at the San Diego Convention Center, located at 111 W Harbor Drive, San Diego, CA 92101....

Approvals and Availability in Europe When it comes to Europe, the process of gaining EMA approval for imetelstat is already underway. Geron's marketing authorization application for the medicine was validated in October 2023. Hopefully, the approval in Europe is just a matter of a bit more time and...

I am trying to improve my understanding. If THIO is not an oligonucleotide, what is it? This article talks about modified oligonucleotides, modified nucleic acids, and new spheres of application. I can see why Novo Nordisk is interested in this area of rapid development. =================== https://...

Is THIO (MAIA) also an oligonucleotide or something different? Rytelo and THIO are similar is someways, and in someways chemically different. They may both be oligonucleotides, but I am not sure (way beyond my knowledge of chemistry). Do Geron & MAIA have overlapping patents? As I remember, Geron hi...

Some thoughts for the last quarter of 2024 Rytelo alone (FDA approved) is just the beginning of new treatments and (hopefully) some cancer cures. Research continues --- blood cancer combinations, with chemotherapy, IMET2.0, oral forms, new patents, European approvals (EMA & MHRA/UK), off-label. The...

Reference Material Telomere length: how the length makes a difference M. Lulkiewicz,1 J. Bajsert,1 P. Kopczynski,2 W. Barczak Abstract Telomerase is perceived as an immortality enzyme that might provide longevity to cells and whole organisms. Importantly, it is generally inactive in most somatic ce...

bp --- My background is in atomic physics (long retired), so I am a novice here. I have believed that cancer, immortal cells, and longevity are somehow all tied together as we try to understand what life is about and how to extend it. From what I have read, there appears to be ongoing discussions ab...

This is just the tip of the iceberg for Rytelo, with many years of research and successes ahead in all sorts of combinations. Rytelo research seems to be revealing to us many of the secrets for the cures to cancer, immortal cells and longer life. Also, IMET2.0 and Rytelo (oral form) are now patente...

The Mighty Mouse: The Impact of Rodents on Advances in Biomedical Research - PMC (nih.gov) https://pubmed.ncbi.nlm.nih.gov/23829104/ Laboratory rats and mice provide ideal animal models for biomedical research and comparative medicine studies because they have many similarities to humans in terms o...

Most on this board believe that EMA and MHRA approvals are inevitable, but no one knows exactly when. At that time, many believe that Geron will decide on a European partner or collaborator with deep pockets. Both Novo Nordisk and Novartis have been mentioned. Here are their current products. Novart...

IMpress interim data (Rytelo alone for AML) has been rumored to be very good. We will see how this affects the TELOMERE combination trial (Rytelo and AbbVie's Venetoclax) for AML with hoped for clinical synergies similar to the very positive preclinical studies. Hopefully patients' immediate needs w...

Pending approval and access by patients in various parts of Europe (EMA and MHRA in the UK) https://everyone.org/blog/geron-imetelstat-ema-approval Geron's Rytelo/imetelstat: When is EMA approval coming for the newest MDS treatment? When is the new treatment for MDS going to be available to patient...